Skip to main content

Table 2 Therapeutic responses of 27 RRMM patients to single-agent circularly permuted TRAIL (CPT) treatment

From: Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Responsea No. of patients (%)
Near-complete response (nCR) 1 (3.7)
Partial response (PR) 8 (29.6)
Minimal response (MR) 4 (14.8)
No change (NC) 3 (11.1)
Progressive disease (PD) 11 (40.7)
ORR (nCR + PR) 9 (33.3)
CBR (nCR + PR + MR) 13 (48.1)
  1. ORR overall response rate, CBR clinical benefit rate, TRAIL tumor necrosis factor-related apoptosis-inducing ligand
  2. aResponses were assessed according to the European Group for Blood and Marrow Transplantation criteria